Akoya Biosciences Q2 revenue $23.2M, up 26% sequentially; COO retiring; FY guidance $96-104M

Akoya Biosciences, Inc.

2024-Q2 EPS reported -$0.74 revenue$41,514,000

Revenue $23.2M, up 26.2% sequentially from Q1 2024; YoY down 1.5% from $23.5M.
Gross margin improved to 57.8% from 45.7% in Q1 2024 and 51.5% in Q2 2023.
Operating loss narrowed to $11.1M from $21.6M in Q1 2024 and $19.2M in Q2 2023.
Updated FY2024 revenue guidance $96-104M; reaffirms operating cash flow breakeven by year-end.
COO Frederic Pla retiring effective August 16, 2024; will assist transition.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Frederic Pla

Chief Operating Officer

Akoya Biosciences, Inc.

Effective: 2024-08-16
Filed: August 5, 2024, 7:59 PM ET

On July 31, 2024, Frederic Pla notified the Company of his intent to retire from his position as Chief Operating Officer of the Company, effective August 16, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Frederic Pla departed as Chief Operating Officer at Akoya Biosciences, Inc..

Action: retire
Role: Chief Operating Officer

Exact text from the filing

On July 31, 2024, Frederic Pla notified the Company of his intent to retire from his position as Chief Operating Officer of the Company, effective August 16, 2024

View on SEC.gov

Source: SEC EDGAR

accession 0001558370-24-010858

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.